AAAAAA
Results: 26-50/1095
Authors:
Malingre, MM
Huinink, WWT
Duchin, K
Schellens, JHM
Beijnen, JH
Citation: Mm. Malingre et al., Pharmacokinetics of oral cyclosporin A when co-administered to enhance theoral absorption of paclitaxel, ANTI-CANC D, 12(7), 2001, pp. 591-593
Authors:
Waltmire, CN
Alberts, DS
Dorr, RT
Citation: Cn. Waltmire et al., Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer, ANTI-CANC D, 12(7), 2001, pp. 595-602
Authors:
Ouenadio, F
Walchshofer, N
Trentesaux, C
Barret, R
Paris, J
Citation: F. Ouenadio et al., Synthesis and antiproliferative activity of [2-(phthaloylamino)alkyl]triphenyl phosphonium derivatives against K562 cell line, ANTI-CANC D, 12(7), 2001, pp. 603-606
Authors:
Godlewski, MM
Motyl, MA
Gajkowska, B
Wareski, P
Koronkiewicz, M
Motyl, T
Citation: Mm. Godlewski et al., Subcellular redistribution of BAX during apoptosis induced by anticancer drugs, ANTI-CANC D, 12(7), 2001, pp. 607-617
Authors:
Ong, SYK
Clarke, SJ
Bishop, J
Dodds, HM
Rivory, LP
Citation: Syk. Ong et al., Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction, ANTI-CANC D, 12(7), 2001, pp. 619-625
Authors:
Hirashima, Y
Kobayashi, H
Nishiguchi, T
Miura, K
Kanayama, N
Citation: Y. Hirashima et al., A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin, ANTI-CANC D, 12(7), 2001, pp. 627-630
Authors:
Kikuchi, Y
Hiramatsu, H
Seto, H
Kita, T
Citation: Y. Kikuchi et al., A rare case of advanced ovarian carcinoma who developed difficulty walking25 days after treatment with weekly paclitaxel, ANTI-CANC D, 12(7), 2001, pp. 631-633
Authors:
Stenkvist, B
Citation: B. Stenkvist, Cardenolides and cancer, ANTI-CANC D, 12(7), 2001, pp. 635-636
Authors:
Pathak, S
Multani, AS
Newman, RA
Narayan, S
Kumar, V
Citation: S. Pathak et al., Oleander extract induces cell death in human but not murine cancer cells, ANTI-CANC D, 12(7), 2001, pp. 637-638
Authors:
Caponigro, F
Avallone, A
Budillon, A
Comella, P
Comella, G
Citation: F. Caponigro et al., Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy, ANTI-CANC D, 12(6), 2001, pp. 489-497
Authors:
Hoff, PM
Saad, ED
Ravandi-Kashani, F
Czerny, E
Pazdur, R
Citation: Pm. Hoff et al., Phase I trial of i.v. administered tirapazamine plus cyclophosphamide, ANTI-CANC D, 12(6), 2001, pp. 499-503
Authors:
Garcia, AA
Muggia, FM
Spears, CP
Jeffers, S
Silberman, H
Pujari, M
Koda, RT
Citation: Aa. Garcia et al., Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2 '-deoxyuridine and leucovorin, ANTI-CANC D, 12(6), 2001, pp. 505-511
Authors:
Polee, MB
Kok, TC
Siersema, PD
Tilanus, NW
Splinter, TAW
Stoter, G
Van der Gaast, A
Citation: Mb. Polee et al., Phase II study of the combination cisplatin, etoposide, 5-fluorouracil andfolinic acid in patients with advanced squamous cell carcinoma of the esophagus, ANTI-CANC D, 12(6), 2001, pp. 513-517
Authors:
van Maanen, MJ
Huitema, ADR
Rodenhuis, S
Beijnen, JH
Citation: Mj. Van Maanen et al., Urinary excretion of thioTEPA and its metabolites in patients treated withhigh-dose cyclophosphamide, thioTEPA and carboplatin, ANTI-CANC D, 12(6), 2001, pp. 519-524
Authors:
Saif, MW
Wilson, RH
Harold, N
Keith, B
Dougherty, DS
Grem, JL
Citation: Mw. Saif et al., Peripheral neuropathy associated with weekly oval 5-fluorouvacil, leucovorin and eniluracil, ANTI-CANC D, 12(6), 2001, pp. 525-531
Authors:
Li, N
van Agthoven, M
Willemse, PHB
Uyl-de Groot, CA
Citation: N. Li et al., A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer, ANTI-CANC D, 12(6), 2001, pp. 533-540
Authors:
Hu, K
Yao, XS
Citation: K. Hu et Xs. Yao, Methyl protogracillin (NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute's anticancer drug screen panel, ANTI-CANC D, 12(6), 2001, pp. 541-547
Authors:
Hashizume, Y
Asakura, T
Oikawa, T
Yamauchi, T
Soda, K
Ohkawa, K
Citation: Y. Hashizume et al., Relationship between cytocidal activity and glutathione-S-transferase inhibition using doxorubicin coupled to stereoisomers of glutathione with different substrate specificity, ANTI-CANC D, 12(6), 2001, pp. 549-554
Authors:
Voeller, DM
Parr, A
Allegra, CJ
Citation: Dm. Voeller et al., Development of human anti-thymidine kinase antibodies, ANTI-CANC D, 12(6), 2001, pp. 555-559
Authors:
Mazar, AP
Citation: Ap. Mazar, The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer, ANTI-CANC D, 12(5), 2001, pp. 387-400
Authors:
Perchellet, EM
Sperfslage, BJ
Qabaja, G
Jones, GA
Perchellet, JP
Citation: Em. Perchellet et al., Quinone isomers of the WS-5995 antibiotics: synthetic antitumor agents that inhibit macromolecule synthesis, block nucleoside transport, induce DNA fragmentation, and decrease the growth and viability of L1210 leukemic cellsmore effectively than ellagic acid and genistein in vitro, ANTI-CANC D, 12(5), 2001, pp. 401-417
Authors:
Yamamoto, W
Verweij, J
de Bruijn, P
de Jonge, MJA
Takano, H
Nishiyama, M
Kurihara, M
Sparreboom, A
Citation: W. Yamamoto et al., Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells, ANTI-CANC D, 12(5), 2001, pp. 419-432
Authors:
Wakita, K
Minami, M
Venkateswarlu, A
Sharma, VM
Ramesh, M
Akahane, K
Citation: K. Wakita et al., Antitumor bicyclic hexapeptide RA-VII modulates cyclin D1 protein level, ANTI-CANC D, 12(5), 2001, pp. 433-439
Authors:
Pessina, A
Raimondi, A
Croera, C
Acchini, M
Mineo, E
Foti, P
Neri, MG
Citation: A. Pessina et al., Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin, ANTI-CANC D, 12(5), 2001, pp. 441-451
Authors:
Misiura, K
Kinas, RW
Kusnierczyk, H
Radzikowski, C
Stec, WJ
Citation: K. Misiura et al., (S)-(-)-Bromofosfamide (CBM-11): synthesis and antitumor activity and toxicity in mice, ANTI-CANC D, 12(5), 2001, pp. 453-458